30 closest matches · ranked by relevance
Dravet Syndrome
Primary: Change in Number of General Tonic-clonic Seizures From Week 8 (Baseline) Visit to Week 12 Visit — 39; 14 General tonic-clonic seizures
Epilepsy · Dravet Syndrome
Primary: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period — -38.94; -13.29 percent change — p=0.0123
Dravet Syndrome (DS)
Primary: Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Full Treatment Period — -8.64; -22.16 percent change — p==0.061
Epilepsy · Dravet Syndrome
Primary: Change In Convulsive Seizures During The Treatment Period Compared To Baseline — 48.7; 45.7; 26.9 percentage reduction — p=0.0299
Epilepsy · Dravet Syndrome · Lennox-Gastaut Syndrome
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment Group — 306; 353; 135; 140 participants
Epilepsy · Dravet Syndrome
Primary: Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs) — 2; 1; 0; 1 Participants
Seizures
Primary: Percentage of Participants With Adverse Events — 88.9; 92.3; 88.2; 90.4 Percentage of participants
Epilepsy
Primary: Percent Change From Baseline in 28-Day Convulsive Seizure Frequency During Ataluren Treatment Period — 723.17 percent change
CDKL5 Deficiency Disorder
Primary: Summary of 28-day Seizure Frequency for Major Motor Seizure Types — 49.17; 54.00; 55.50; 45.03 Seizures per day
Dravet Syndrome · Lennox Gastaut Syndrome · Epileptic Encephalopathy
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 75.5 percentage of participants
Dravet Syndrome · Seizure Disorder
Primary: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8…
Dravet Syndrome
Primary: Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) Period — -3.18; -0.65 Convulsive seizures…
CDD
Primary: Change From Baseline in Median Monthly Convulsive Seizure Frequency — 88.429 Number of monthly seizures
Dravet Syndrome
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Open-label Extension (OLE) Treatment Period — 98.1 percentage of participants
Epilepsy
Primary: Summary of 28-day Seizure Frequency for Sum of Individual Seizures and Clusters for 52-week OLE Period (Mean Percent Change & Standard Deviation) — -31.23; NA; 122.10…
Sturge-Weber Syndrome
Primary: Number of Seizures Per Month — 33.5; 30.0; 3.0; 0.5 Seizures per month
Photosensitive Epilepsy
Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001
Seizures
Primary: Maximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol — 59.03; 110.5; 256.9; 28.71 nanograms/milliliter (ng/mL)
Sturge-Weber Syndrome
Primary: List Sorting Working Memory Test — 37.14; 39.14 T-score
Tuberous Sclerosis Complex
Primary: Cognitive Assessment Scores and Developmental Impact — 83.9; 80.9; 97.3; 85.0 score on a scale — p=0.8681
PCDH19-Related Epilepsy
Primary: Summary of 28-day Seizure Frequency Through 17 Week Post-Baseline Phase (Median Percent Change) — -23.97; -61.52 Median % Change in Number of Seizures
Reflex Epilepsy, Photosensitive
Primary: The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition — 0.57; 1.38; 1.58; 6.80 Units on a scale
Childhood Absence Epilepsy · Petit Mal Epilepsy · Epilepsy
Primary: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy — 81; 43; 85 Participants — p=<0.001
15q Duplication Syndrome · CDKL5 Deficiency Disease
Primary: Percent Change From Baseline in Motor Seizure Frequency Per 28 Days During the Maintenance Period — 11.7; -23.6 percent change
Epilepsy · Lennox Gastaut Syndrome
Primary: Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period — -41.86; -37.16; -17.17 percentage change — p=0.0047
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Primary: Reported Change in Seizures Frequency From Baseline at 13 Weeks — 4.4; 189.5 seizures/two weeks
Epilepsy · Lennox-Gastaut Syndrome
Primary: Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period — -43.90; -21.80 percentage change — p=0.0135
Lennox-Gastaut Syndrome
Primary: Number of Seizure After Treatment by tDCS — 80.67; 93.43; 35.53; 93.14 seizures — p=<0.05
Epileptic Encephalopathy · Continuous Spike and Wave During Sleep
Primary: Ratio of Spike-Wave Index (SWI) During First Hour of Nonrapid Eye Movement (NREM) Sleep at Week 6 — -0.02; 0.01 Log-transformed ratio — p=0.4326
Epilepsy · Generalized Tonic-clonic Seizures
Primary: The Percent Change From the Combined Baseline (4-week Retrospective Baseline and 4-week Prospective Baseline) in the Generalized Tonic-clonic Seizure Frequency Per Week…